REPORT SCOPE
INTRODUCTION
Through the late 1980s, the vaccine market was beset by limited portfolios and profitability. Recent technological breakthroughs in understanding disease mechanisms, probably necessitated by pandemics and vaccine shortages, have provided momentum for research in the past decade or so. This is apparent from the increased research, patent, and regulatory activity in this area. Breakthroughs in molecular biology, immunology, and computing promise a bright future for the treatment of not only infectious diseases but also for treatment of conditions such as chronic infections, cancer, autoimmune diseases, allergies, and even nicotine addiction and high blood pressure using vaccine technologies. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvants, and vaccine manufacturing.
The market has also witnessed significant strategic alliance activity, changes in centers of manufacture, and an increase in the importance of hitherto small (such as adult vaccines) or nonexistent (therapeutic) segments.
Most of all, international health agencies have recognized the importance of disease prevention and stupendous funding is being channelized into research, purchase, and administration of vaccines.
SCOPE OF STUDY
This report contains:
- Descriptions of various human and veterinary vaccines that treat infectious diseases, chronic infections, cancer, auto-immune diseases, allergies, high blood pressure and addictions
- The current market status of the vaccine industry, with trends and forecasts for growth over the next 5 years
- The latest vaccine research findings in prophylactic and therapeutic areas
- Analysis of significant vaccine-related patents in the Unites States and Europe
- An overview of the regulatory environment.
METHODOLOGY
BCC's methodology for market analysis and forecast projections includes both primary and secondary research sources. Market growth calculations take into account all factors that are likely to spur or inhibit market growth. Revenue figures are not corrected for inflation.
INFORMATION SOURCES
Data were compiled from industry experts and other stakeholders as well as various secondary sources such as government, nongovernment industry stakeholders, technology and market publications, and other public research data sources.
ABOUT THE AUTHOR
Vanita Khetan is a market analyst who has authored several BCC technology market research reports. She holds a bachelor's degree in chemistry and a post graduate degree in management. During her career, she has analyzed U.S., European, and Asian markets in biotechnology, pharmaceuticals, medical devices, wound care, and surgical goods. She has also worked in the Indian vaccine industry for about 2 years.
